We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of Dehydroepiandrosterone (DHEA) Treatment for in Vitro Fertilization (IVF)

This study has been terminated.
(Failure to recruit sufficient participants.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00419913
First Posted: January 9, 2007
Last Update Posted: April 2, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Foundation for Reproductive Medicine
Information provided by:
Center for Human Reproduction
  Purpose

Our long term goal is to elucidate the role of DHEA on follicular dynamics in the human ovary and to better understand the interaction of DHEA supplementation with other treatments for ovulation induction, especially among older reproductive age women.

The specific hypothesis behind the proposed research is that DHEA is a regulator of follicular dynamics acting in the early pre-gonadotropin dependent stage of initial primordial follicle recruitment and growth.


Condition Intervention Phase
Infertility Decreased Ovarian Reserve Dietary Supplement: Dehydroepiandrosterone Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Placebo-Controlled Trial of Dehydroepiandrosterone (DHEA) Treatment for Two Months Before Starting Ovulation Induction for in Vitro Fertilization (IVF)

Resource links provided by NLM:


Further study details as provided by Center for Human Reproduction:

Primary Outcome Measures:
  • Clinical Pregnancy per cycle of treatment [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Embryos per cycle of treatment [ Time Frame: 1 year ]
  • Oocytes per cycle of treatment [ Time Frame: 1 year ]

Enrollment: 8
Study Start Date: January 2007
Study Completion Date: January 2008
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Dehydroepiandrosterone (DHEA) 25mg tid
Dietary Supplement: Dehydroepiandrosterone
DHEA 25 mg tid
Placebo Comparator: B Dietary Supplement: Dehydroepiandrosterone
DHEA 25 mg tid

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Women over the age of 40 and less than 45 years old presenting for IVF treatment.
  • Willingness to sign informed consent for study randomization.
  • Willingness to participate in 2 months pre-IVF treatment.

Exclusion Criteria:

  • Medical condition that would contraindicate pregnancy, ovulation induction or general anesthesia.
  • Family history of significant genetic disease, or factor V Leiden thrombophilia.
  • Inability to present for monitoring visits.
  • Inability to follow medication instruction.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00419913


Locations
United States, New York
Center for Human Reproduction
New York, New York, United States, 10021
Austria
Institute fur Reproduktionsmedzin und Endokrinologie
Bregenz, Austria
Sponsors and Collaborators
Center for Human Reproduction
Foundation for Reproductive Medicine
Investigators
Principal Investigator: David Barad, MD Center for Human Reproduction
  More Information

Publications:
Responsible Party: Dr. David H. Barad, Center for Human Reproduction
ClinicalTrials.gov Identifier: NCT00419913     History of Changes
Other Study ID Numbers: CHR2006 1.0
First Submitted: January 7, 2007
First Posted: January 9, 2007
Last Update Posted: April 2, 2008
Last Verified: March 2008

Keywords provided by Center for Human Reproduction:
Ovulation Induction
In vitro Fertilization
Pregnancy

Additional relevant MeSH terms:
Infertility
Genital Diseases, Male
Genital Diseases, Female
Dehydroepiandrosterone
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs